Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients.
biomarkers
circulating tumor cells
homologous repair deficiency
metastatic castrate-resistant prostate cancer
radium-223
γH2AX
Journal
Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030
Informations de publication
Date de publication:
05 Dec 2019
05 Dec 2019
Historique:
entrez:
10
1
2020
pubmed:
10
1
2020
medline:
10
1
2020
Statut:
epublish
Résumé
Radium-223 improves overall survival in patients with metastatic castration-resistant prostate cancer to the bone. Radium-223 causes double-strand DNA breaks and produces γH2AX, a potential biomarker for response. We examined the feasibility of tracking γH2AX positivity and numeration in circulating tumor cells. Ten patients with biopsy-confirmed symptomatic M1b castration-resistant prostate cancer received radium-223 as standard of care and were assessed for γH2AX level changes following doses 1, 3 and 6. Trend tests confirmed that patients with ≥50% increase in circulating tumor cells positive for γH2AX postradium-223 therapy had a lower risk of death (p = 0.035). Regular interval measurements of γH2AX are feasible. The potential correlation between γH2AX changes and overall survival warrants further investigation.
Identifiants
pubmed: 31915536
doi: 10.2144/fsoa-2019-0092
pmc: PMC6920735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
FSO437Informations de copyright
© 2019 Jonathan Chatzkel.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure Funding support was provided by Bayer. J Zhang received consulting fees from Bayer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Références
Eur Urol. 2017 Jul;72(1):34-42
pubmed: 28259476
Urology. 2005 Apr;65(4):713-8
pubmed: 15833514
Clin Cancer Res. 2007 Dec 1;13(23):7053-8
pubmed: 18056182
Asian J Androl. 2014 May-Jun;16(3):401-6
pubmed: 24589464
J Clin Oncol. 2011 Apr 20;29(12):1556-63
pubmed: 21422424
Eur Urol. 2016 Jun;69(6):992-5
pubmed: 26724258
Clin Genitourin Cancer. 2017 Dec;15(6):e969-e975
pubmed: 28545997
Cancer Res. 2002 Jun 1;62(11):3120-5
pubmed: 12036923
EMBO J. 2010 Apr 21;29(8):1446-57
pubmed: 20360682
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
J Clin Oncol. 2018 Apr 1;36(10):991-999
pubmed: 29261439
Curr Opin Investig Drugs. 2009 Dec;10(12):1346-58
pubmed: 19943206
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Eur Urol. 2018 May;73(5):687-693
pubmed: 29429804
Nat Rev Cancer. 2008 Dec;8(12):957-67
pubmed: 19005492
Clin Cancer Res. 2007 Apr 1;13(7):2023-9
pubmed: 17404082
Ann Nucl Med. 2018 Feb;32(2):142-148
pubmed: 29285670
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Br J Cancer. 2014 Mar 18;110(6):1663-72
pubmed: 24556621
J Clin Oncol. 2002 Oct 1;20(19):3972-82
pubmed: 12351594
Clin Genitourin Cancer. 2018 Dec;16(6):e1133-e1139
pubmed: 30104161
Cancer Biol Ther. 2003 May-Jun;2(3):233-5
pubmed: 12878854
J Clin Oncol. 2018 Feb 20;36(6):572-580
pubmed: 29272162
Urol Oncol. 2014 Aug;32(6):761-8
pubmed: 24929891
Lancet Oncol. 2009 Mar;10(3):233-9
pubmed: 19213602
Front Oncol. 2018 Feb 05;8:16
pubmed: 29459887
BJU Int. 2001 Aug;88(3):226-30
pubmed: 11488734
Prz Menopauzalny. 2016 Dec;15(4):215-219
pubmed: 28250726
Ann Oncol. 2017 May 1;28(5):1090-1097
pubmed: 28453701
J Clin Oncol. 2003 Apr 1;21(7):1232-7
pubmed: 12663709
J Clin Oncol. 2005 Mar 1;23(7):1420-30
pubmed: 15735118
Cancer Res. 2009 Apr 1;69(7):2912-8
pubmed: 19339269
JAMA. 2005 Jul 13;294(2):238-44
pubmed: 16014598
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Ann Surg Oncol. 2013 Dec;20(13):4322-9
pubmed: 23943022
Mutat Res. 2013 Jul-Sep;753(1):24-40
pubmed: 23416207
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Eur Urol. 2019 Aug;76(2):170-176
pubmed: 30293905
J Oncol. 2010;2010:617421
pubmed: 20016752